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Abstract
Introduction: Systemic inhibition of the inflammatory enzyme cyclooxygenase (COX) 2 decreases the risk of breast
cancer and its recurrence. However, the biology of COX-2 in the multicellular tumor microenvironment is poorly
defined.
Methods: Mammary tumor onset and multiplicity were examined in ErbB2 transgenic mice that were deficient in
mammary epithelial cell COX-2 (COX-2MECKO) compared to wild type (WT) mice.
Tumors were analyzed, by real time PCR, immune-staining and flow cytometry, for proliferation, apoptosis,
angiogenesis and immune microenvironment. Lentiviral shRNA delivery was used to knock down (KD) COX-2 in
ErbB2-transformed mouse breast cancer cells (COX-2KD), and growth as orthotopic tumors was examined in
syngenic recipient mice, with or without depletion of CD8+ immune cells.
Results: Mammary tumor onset was delayed, and multiplicity halved, in COX-2MECKO mice compared to WT.
COX-2MECKO tumors showed decreased expression of Ki67, a proliferation marker, as well as reduced VEGFA, its
receptor VEGFR2, endothelial NOS and the vascular endothelial marker CD31, indicating reduced tumor
vascularization. COX-2MECKO tumors contained more CD4+ T helper (Th) cells and CD8
+ cytotoxic immune cells
(CTL) consistent with increased immune surveillance. The ratio of Th markers Tbet (Th1) to GATA3 (Th2) was higher,
and levels of Retnla, a M2 macrophage marker, lower, in COX-2MECKO tumor infiltrating leukocytes compared to
WT, suggesting a prevalence of pro-immune Th1 over immune suppressive Th2 lymphocytes, and reduced
macrophage polarization to the immune suppressive M2 phenotype. Enhanced immune surveillance in
COX-2MECKO tumors was coincident with increased intratumoral CXCL9, a T cell chemoattractant, and decreased
expression of T lymphocyte co-inhibitory receptors CTLA4 and PD-1, as well as PD-L1, the ligand for PD-1. PD-L1
was also decreased in IFNg-treated COX-2KD mouse mammary cancer cells in vitro and, compared to control cells,
growth of COX-2KD cells as orthotopic tumors in immune competent mice was markedly suppressed. However,
robust growth of COX-2KD tumor cells was evident when recipients were depleted of CD8+ cells.
Conclusions: The data strongly support that, in addition to its angiogenic function, tumor cell COX-2 suppresses
intratumoral cytotoxic CD8+ immune cell function, possibly through upregulation of immune checkpoints, thereby
contributing to tumor immune escape. COX-2 inhibition may be clinically useful to augment breast cancer
immunotherapy.
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Introduction
The inducible form of cyclooxygenase (COX), COX-2,
and one of its pro-inflammatory products, prostaglandin
(PG) E2, are strongly implicated in a range of human
cancers including breast cancer [1,2]. Global deletion or
pharmacological inhibition of COX-2 suppressed tumor-
igenesis in mice [3,4] and humans [5]. PGE2 signals
through multiple pro-tumor pathways, including PI3K/
AKT, RAS-MAPK/ERK and Gs-axin-ß-catenin signaling,
to increase tumor cell survival, inhibit apoptosis,
increase cancer cell motility, stimulate angiogenesis and
inhibit immune surveillance [6].
In the last decade it has become clear that the tumor
microenvironment is critical for tumors to survive and
progress. In addition to vascular supply, the interplay of
tumor cells with non-malignant cells in the stroma pro-
vides growth, survival and motility advantages. A central
part of the tumor microenvironment is infiltration of
immune cells, which can positively or negatively influence
tumor progression depending on their differentiation [7,8].
Tumor rejection is favored through T helper 1 (Th1)-
derived cytokines that drive antigen-presenting and pro-
immune M1 macrophage functions, and by the direct
tumoricidal actions of CD8+ cytotoxic T lymphocytes
(CTLs) and natural killer (NK) cells [6]. However, as
tumors progress, soluble mediators and cellular interac-
tions are thought to reprogram immune cells to type 2
functions so that Th2 lymphocyte-derived cytokines polar-
ize macrophages to the M2 phenotype to suppress CTLs,
promote angiogenesis and support tumor growth [6,9]. In
breast cancer, poor prognosis is associated with elevated
Th2 lymphocytes and tumor-associated macrophages
(TAM), while Th1 lymphocytes, CTLs and NKs correlate
with enhanced survival [8,10], raising intense interest in
therapeutic approaches to modify the tumor immune
microenvironment. COX-2-derived PGE2 has emerged as
a tumor-derived mediator that contributes to development
of immune tolerance [11-13]. Several studies report the
association of tumor COX-2 with infiltrating T cells, den-
dritic cells, myeloid derived suppressor cells and macro-
phages [14-17], while PGE2 has been linked to immune
suppression in hepatocellular carcinoma [18], lung [19],
ovarian [20] and breast [14,15] cancers. The mechanisms
through which COX-2/PGE2 suppress immune function
are poorly defined; however, PGE2 suppressed the ability
of mature CTLs to kill murine plasmocytoma cells [21]
and inhibited Th1 generation of interferon g (IFNg)
[22,23], a cytokine that is critical to sustain anti-tumor
immune function [6,24].
We reported that selective deletion of mammary epithelial
cell (MEC) COX-2 (COX-2MECKO) delayed carcinogen-
induced mammary tumor onset coincident with enhanced
markers of anti-tumor type 1 immunity [17]. Chemical
carcinogens are generally not, however, considered signifi-
cant in human breast cancer etiology; therefore, in the cur-
rent study, we investigated the role of tumor cell COX-2-
derived mediators in ErbB2 (HER-2/neu)-induced mam-
mary tumorigenesis. ERBB2 gene amplification or overex-
pression of the HER-2 protein has been identified in 25% to
34% of human breast cancers [25,26]. ErBb2 mouse models
show remarkable morphological resemblance to some
forms of human breast cancer and accurately recapitulate
the hallmark changes associated with the early stages of
human breast cancer [27]. In COX-2MECKO mice trans-
genic for an activated ErbB2 mutant, we determined
delayed tumor onset and reduced tumor multiplicity, as
well as reduced tumor vascularization, compared to wild
type (WT). Deletion of COX-2 in tumor cells also signifi-
cantly impaired maintenance of pro-tumorigenic lymphoid
and myeloid cell functions thereby facilitating enhanced
immune surveillance.
Methods
Mice and tumor tissue collection
All procedures were conducted in accordance with
National Institutes of Health regulations and were
approved by the Institutional Animal Care and Use
Committee of the University of Pennsylvania.
Floxed COX-2 mice, generated by flanking the COX-2
gene between introns 5 and 8 with loxP sites (COX-
2flox/flox), were backcrossed fully (>9 generations) onto
an FVB background and are denoted as wild type (WT)
mice. COX-2flox/flox mice were crossed with FVB mice
expressing Cre-recombinase under control of the mouse
mammary tumor virus (mmtv) promoter (Cremmtv),
which is used widely to target transgene expression to
MEC. The resulting mice were termed COX-2MECKO
and their characterization is described in our previous
work [17]. WT and COX-2MECKO were crossed with
mice transgenic for the ErbB2 (HER2/c-neu) oncogene
carrying Eactivating Val664 to Glu664 mutation (Jackson
Laboratory, Bar Harbor, ME, USA), also expressed
under the control of mmtv promoter. Genotype verifica-
tion was performed by conventional PCR using primers
listed in Table 1.
Table 1 Genotyping primer sequences
Gene Forward (F) and Reverse (R) primer sequences
COX-2 F:TGA GGC AGA AAG AGG TCC AGC CTT
R:ACC AAT ACT AGC TCA ATA AGT GAC
Cremmtv F:TCG ATG CAA CGA GTG ATG AGG
R:ACG AAC CTG GTC GAA ATC AGT
Erbb2 F:GGACATCCAGGAAGTTCAGGGTTAC
R:ACAGGAGCCAGTTGGTTATTCTTG
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Mice were palpated weekly and considered tumor
bearing if a palpable mammary mass persisted for more
than one week. On necropsy, tumors were counted and
isolated from surrounding tissues, after which they were
either frozen and stored at -80°C for RNA extraction or
fixed in Prefer (Anatech, Battle Creek, MI, USA) over-
night and paraffin embedded or digested to obtain single
cell suspension for flow cytometry and microbead
separation. For tissue digestion, tumors were washed
with (D)MEM/F12 + 5% fetal bovine serum (FBS) +
gentamycin 50 mg/ml, minced and placed in digestion
buffer consisting of 9 parts of wash buffer +1 part
collagenase/hyaluronidase (StemCell Technologies, Van-
couver, BC Canada). After two hours shaking at 37°C,
the suspensions were centrifuged at 1,000 rpm for five
minutes. Pellets were washed and treated with red cell
lysis buffer (1 part HBSS+2%FBS + 3 parts NH4Cl) and
then with Trypsin-ethylenediaminetetraacetic acid
(EDTA) 0.25% (Gibco, Grand Island, NY, USA), fol-
lowed by Dispase and DNase (StemCell Technologies).
Thereafter, cell pellets were passed through a 40 μm cell
strainer, counted and re-suspended either in fluores-
cence-activated cell sorting (FACS) buffer for flow cyto-
metry (description below) or in degassed MACS buffer
(PBS + 0.5% BSA + 2 mM EDTA) for positive selection
of CD45+ cells using CD45-microbeads (Miltenyi Biotec,
Auburn, CA, USA) according to the manufacturer’s
instructions.
NAF mammary tumor cell line culture, transduction, and
treatments
The NAF tumor cell line, which was generated from mam-
mary tumors of ErbB2-transgenic mice, was kindly pro-
vided by Dr. Lewis Chodosh (University of Pennsylvania).
NAF were cultured in (D)MEM medium containing 10%
FBS, 1% L-glutamine and 1% penicillin/streptomycin. For
viral transduction, 15,000 cells/well were plated on 96-well
plates. Mission plKO.1-puro Transduction Lentiviral Parti-
cles (20 μl), carrying either non-target control small hair-
pin RNA (shRNA) or COX-2 shRNA (Sigma, St. Louis,
MO, USA), at 1 × 107 TU/ml were added to the wells with
8 μg/ml protamine sulfate. After 18 hours, lentiviral parti-
cles were removed and cells kept in medium containing
2 μg/ml puromycin (Sigma) to select for transduced cells.
COX-2 knock down in COX-2 shRNA transduced NAF
cells (NAF COX-2KD) compared to non-target shRNA
transduced cells (NAF nt) was verified by Q-PCR.
Cells were serum starved for 24 hours and then treated
with 10 ng/ml IFNg(PeproTech, Rocky Hill, NJ, USA ),
with or without 250 nM PGE2 (Cayman Chemicals, Ann
Arbor, MI, USA). Fresh IFNg and PGE2 were added
24 hours later, and cells were harvested (0.25% Trypsin-
EDTA) after 48 hour treatment, washed and re-suspended
in FACS buffer for flow cytometry analysis.
Bone marrow-derived macrophage isolation and culture
Bone marrow-derived macrophages (BMDM) were iso-
lated as described [28]. Femurs from female mice were
flushed with (DMEM and cells pelleted (1,000 rpm) and
incubated at 37°C for 24 hours in (DMEM containing
10% FBS, 1% L-glutamine, and 1% penicillin/streptomy-
cin. Non-adherent cells were collected and plated in
L929 cell-conditioned medium (LCCM). To make
LCCM, medium collected from L929 cells (American
Type Culture Collection, Manassas, VA, USA), that
were split 1:5 and grown to confluency, was mixed 1:5
with (DMEM with 10% FBS, 1% L-glutamine, and 1%
penicillin/streptomycin. Purity (approximately 99%) was
verified by flow cytometry for F4/80 and CD11b (not
shown). BMDM were plated (0.5 × 106 cells/well) in
LCCM. At 100% confluency, media was replaced with
(DMEM. After 24 hours, cells received vehicle, or M1
polarizing mix (100 ng/ml lipopolysaccharide (LPS;
Sigma) and 20 ng/ml IFNg (Peprotech)), or M2 polarizing
mix (20 ng/mL IL-4 and 10 ng/mL IL-13; Peprotech),
with or without 250 nM PGE2 (Cayman Chemicals).
Supernatants were removed 18 hours later and cells lysed
for RNA isolation.
Real Time RT-PCR
Total RNA from tumors and cells was isolated (RNeasy,
Qiagen, Germantown, MD, USA), and reverse transcribed
(TaqMan Reverse Transcriptase, Applied Biosystems,
Carlsbad, CA, USA), according to the manufacturer’s
instructions. Real time quantitative (Q)-PCR of all genes,
including 18S ribosomal RNA, was performed using
inventoried gene expression assays and TaqMan Universal
PCR Master Mix from Applied Biosystems. PCR products
were detected in ABI-PRISM 7900 sequence detection sys-
tems (Applied Biosystems). Results were analyzed using
the comparative Ct method, and normalized to 18S RNA.
Immunohistochemistry
Paraffin embedded tumor tissues were sectioned (4 μm).
After de-paraffinization and rehydration, endogenous per-
oxidase was blocked with 3% hydrogen peroxide. Heat
induced epitope retrieval was performed with 1 mM
EDTA (Invitrogen, Grand Island, NY, USA). After over-
night blocking at 4°C with 5% donkey serum (Sigma) +
0.1% Triton 100× (Sigma), sections were incubated with
primary antibodies overnight at 4°C as follows: anti-Ki67
(Abcam, Cambridge, MA, USA,1:50 dilution), anti-CD31
(Abcam, 1:200 dilution) or anti-CXCL9 (Aviva Systems
Biology, San Diego, CA, USA 1:125 dilution). Thereafter,
the Polink-2 HRP Plus AEC System for Immunohisto-
chemistry (Golden Bridge International, Inc, Mukillteo,
WA, USA) was used, according to the manufacturer’s
instructions. Slides were then counterstained with hema-
toxylin (Vector Laboratories, Burlingame, CA, USA), and
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mounted (Aqua-Mount; Lerner Laboratories, Pittsburgh,
PA, USA). Images were taken with a Nikon Eclipse E600
microscope using ACT-1 imaging program (Nikon Instru-
ments Inc., Hicksville, NY, USA).
Flow cytometry
Single cell suspensions from tumor digestions (above)
were centrifuged, washed and re-suspended in FACS buf-
fer (PBS + 2% FBS +1 mM EDTA + 0.01% sodium azide),
1 × 106 cell/100 μl/tube. After a five minute incubation
with rat anti-mouse CD16/CD32 (Mouse BD Fc Block, BD
Pharmingen, Franklin Lakes, NJ, USA), 1 μg/ml of fluores-
cein isothiocyanate (FITC) conjugated anti-CD3, PE con-
jugated anti-CD4, and AF647 conjugated anti-CD8a, or PE
conjugated anti-F4/80 and AF647 conjugated anti-CD86
antibodies (Invitrogen) were added. OneComp eBeads
(eBioscience, San Diego, CA, USA) were incubated with
anti-CD3 or anti-CD4 or anti-CD8a antibodies to perform
compensation for spectral overlap. NAF COX-2KD and
NAF nt (1 × 106 cell/100 μl), were incubated with PE con-
jugated anti-PD-L1 antibody (Biolegend, San Diego, CA
USA). After a 30-minute incubation, cells were washed
and re-suspended in 500 μl FACS buffer. Unstained tumor
cells and cells incubated with isotype control rat anti-
mouse antibody were used as negative controls. FACS
analysis was performed on a BD FACSCalibur machine
(BD Biosciences, San Jose, CA, USA). Data was analyzed
using FlowJo Research Flow Cytometry Analysis Software
(TreeStar, Ashland, OR USA).
Orthotopic tumor growth and CD8+ depletion
NAF COX-2KD and NAF nt tumor cells were injected
into the #4 and #9 mammary glands (1 × 106 cells/gland
in 100 μl Hanks Balanced Salt Solution) of normal WT
female mice between 8 to 14 weeks of age. Orthotopic
tumor volume was determined weekly using standard cali-
per measurement. For CD8+ depletion experiments, mice
were injected intraperitoneally with 200 μg of an anti-CD8
or isotype control antibody (BioXCell, West Lebanon, NH,
USA), four days and again two days prior to injection of
tumor cells, and then twice weekly for a further four
weeks. Depletion of CD8+ cells was confirmed by flow
cytometry of erythrocyte lysed whole blood (ACK Lysing
Buffer, Invitrogen), four days and again four weeks after
tumor cell injections.
Statistical analysis
Statistical analyses were performed using Prism (GraphPad
Software, Inc., La Jolla, CA, USA). As appropriate, com-
parisons were made using logrank analysis, unpaired t-test
(with Welch’s correction when variances were significantly
different by F-test), Mann Whitney test (when the data
distribution was not normal), or, for multiple group
comparisons, analysis of variance (ANOVA) followed by
Bonferroni’s multiple comparison test.
Results
Tumor onset, development, and vascularization in WT
and COX-2 MECKO mice
The current investigation was designed to study the role
of MEC COX-2 in mammary tumor development, with
the goal of elucidating whether and how targeted inhibi-
tion of COX-2 in epithelial cells affects the disease. In
our previous study we confirmed COX-2 deletion in
MEC isolated from COX-2MECKO mice by Q-PCR and
Western blotting, and loss of PGE2 generation by COX-
2MECKO cells was established by mass spectrometry
[17]. COX-2 expression and PGE2 production were
unchanged in peripheral macrophages isolated from
COX-2MECKO compared to WT confirming the selec-
tivity of the deletion [17]. In the current study, tumor
onset was significantly delayed in COX-2MECKO mice
compared to their WT littermates (Figure 1A). On
necropsy, COX-2MECKO mice had significantly fewer
tumors compared to WT (Figure 1A). Consistent with
these observations, cell proliferation appeared higher in
WT tumors, as indicated by higher levels of mRNA for
the proliferation marker Ki67 in WT compared to
COX-2MECKO tumors (Figure 1B). Markers for apopto-
sis (caspase3) and autophagy (Lc3) were not different
between the two genotypes (Figure 1B). Abundant
expression of Ki67 protein in WT, but not COX-
2MECKO, tumors was confirmed by immunohistochem-
istry (Figure 1C).
Q-PCR analysis of tumors revealed lower expression
levels of CD31, an endothelial marker, endothelial (e)
NOS, the angiogenic factor VEGFA and its receptor
VEGFR2 (Figure 2A), in COX-2MECKO compared to
WT. Although no difference was observed in mRNA
levels of the lymphangiogenic factor VEGFC, its recep-
tor VEGFR3 was significantly lower in COX-2MECKO
tumors (Figure 2A). Immunostaining for CD31 revealed
a denser blood vessel network in WT tumors, confirm-
ing suppressed angiogenesis in COX-2MECKO tumors
(Figure 2B).
Subpopulations and phenotypes of tumor infiltrating
immune cells in WT and COX-2MECKO tumors
WT and COX-2MECKO tumors were analyzed by flow
cytometry and Q-PCR to compare the populations of
infiltrating immune cells and their phenotypes. By flow
cytometry, there was no difference in the total number
of F4/80+ TAMs between WT and COX-2MECKO
tumors (Figure 3A). COX-2MECKO tumors did, however,
have significantly higher numbers of CD3+CD4+ cells, a
population that includes Th1, Th2, and regulatory T (Treg)
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cells, as well as CD3+CD8+ CTLs and CD3-CD8+ cells,
encompassing NK and dendritic cells (Figure 3A). To
further define their functional identify, tumor-infiltrating
leukocytes (TILs) were isolated using magnetic microbeads
coated with a pan-leukocyte marker CD45 and cells ana-
lyzed by Q-PCR for phenotypic markers and cytokines
(Figure 3B). The ratio of Tbet (Th1 marker)/GATA3 (Th2
marker) tended to be higher in COX-2MECKO tumors
Figure 1 Tumor onset, multiplicity and cell proliferation were suppressed in COX-2MECKO tumors. COX-2MECKO tumors are denoted as
KO. (A) Percent of tumor free mice against weeks of age. Mean tumor free time for COX-2MECKO mice was 29 weeks versus 23 weeks for WT
(left graph, n = 13 to 19). The right graph shows tumor multiplicity as number of tumors per mice at necroscopy (n = 14 to 18). (B) Gene
expression levels of Ki67 (proliferation), Caspase3 (apoptosis) and Lc3 (autophagy) in whole tumors by Q-PCR (n = 8 to 18). (C)
Immunohistochemistry staining for Ki67 (dark red-brown) in sections of paraffin embedded WT and COX-2MECKO tumors (image shown is
representative of n = 4). Cell nuclei are counterstained with hematoxylin. The bar on the KO panel indicates 20× magnification. Data in column
graphs are mean ± sem. P values are compared to WT; *P < 0.05. COX, cyclooxygenase; KO, knock out; WT, wild type.
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compared to WT (Figure 3B), suggesting a prevalence of
CD3+CD4+ Th1 over Th2 lymphocytes, when MEC COX-
2-derived mediators are absent. Further, mRNA levels for
either Tbet alone or the Tbet/GATA3 ratio were signifi-
cantly correlated with CD4 mRNA in COX-2MECKO, but
not WT, tumors (data not shown). Gene expression of
FoxP3, a marker for Treg, was not altered and there was no
difference in mRNA for macrophage type 1 cytokines
TNFa and IFNg or an M1 macrophage marker CD86, in
CD45+ TILs, suggesting no major change in M1 polariza-
tion in this disease model. COX-2-derived PGE2 has been
implicated in driving the immune suppressive phenotype
typically associated with TAM [6]. Indeed, exogenous
PGE2 treatment significantly increased the expression of
M2 marker Arginase 1, a key enzyme in suppression of T
cell function, in both M1 and M2 polarized bone-marrow
derived macrophages (Figure 3C). In tumors, although
arginase 1 mRNA levels were similar in TILs from COX-
2MECKO and WT tumors, another M2 marker, Retnla,
was significantly decreased in COX-2MECKO (Figure 3B).
Taken as a whole, our flow cytometry, immune staining
and CD45+ cell expression analysis indicates that absence
Figure 2 Angiogenesis was suppressed in COX-2MECKO tumors. COX-2MECKO tumors are denoted as KO. (A) Gene expression levels for
CD31, eNOS, VEGFA, VEGFC, VEGFR2 and VEGFR3 in whole tumors by Q-PCR. Data are mean ± sem of n = 8 to 18. P values are compared to
WT. *P < 0.05. (B) Immunohistochemistry staining for CD31 (dark red-brown) in sections of paraffin embedded WT and COX-2MECKO tumors
(image is representative of n = 6). Cell nuclei are counterstained with hematoxylin. The bar on the KO panel indicates 20× magnification. COX,
cyclooxygenase; KO, knock out; WT, wild type.
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of epithelial COX-2-derived mediators augments Th1 and
cytotoxic immune function and reduces immune suppres-
sive macrophage function in the mammary tumor
microenvironment.
COX-2 may enhance immune tolerance through
suppression of T cell recruitment and activation
Our data thus far indicates a significant contribution of
mammary epithelial COX-2-derived mediators to pro-
tumor immune function, particularly T lymphocyte and
cytotoxic immune cell function, in the tumor microen-
vironment. We next examined pathways that control
T cell recruitment, activation and function. In breast
cancer, tumor cell expression of the chemokines CXCL9
and 10 recruits lymphocytes, improves survival in
mouse models and human studies [29,30], and PGE2
inhibits expression of both chemokines in breast cancer
cells in vitro [12]. Paraffin embedded sections of WT
and COX-2MECKO tumors showed substantially higher
levels of CXCL9 expression, by immunohistochemistry,
in COX-2MECKO tumors, and this staining was evident
throughout the tumor cells (Figure 4A). WT tumors, in
contrast, showed weak CXCL9 staining (Figure 4A).
T cell activation requires binding of T cell receptors to
antigen and is regulated by a balance of co-stimulatory
and co-inhibitory receptor-ligand interactions. T cell
CD28 receptor engagement by CD80 or CD86, expressed
on antigen presenting cells, provides the additional signal
necessary for T cell activation. The same ligands can,
alternatively, drive T cells to a state of anergy through
binding to cytotoxic T lymphocyte antigen 4 (CTLA-4)
[31]. Inhibition of T cell function is also directed through
binding of programmed death ligand 1 (PD-L1) to its
receptor, PD-1, expressed on the T cell surface [32]. In
our study, gene expression levels for both inhibitory
receptors CTLA4 and PD-1, as well as PD-L1, were
decreased in COX-2MECKO tumors compared to WT,
suggesting suppressed signaling through co-inhibitory
pathways (Figure 4B). Both cancer cells and tumor infil-
trating myeloid cells are considered as sources of PD-L1
expression in the tumor microenvironment [33,34]. We
did not observe any change in PD-L1 mRNA levels in
CD45+ TILs from COX-2MECKO and WT tumors (data
not shown), suggesting that tumor cell PD-L1 was sup-
pressed by COX-2 deficiency. Indeed, NAF COX-2KD,
which, compared to NAF nt, grew poorly as orthotopic
tumors in immune competent syngenic mice (Figure 5B)
also produced substantially less PD-L1 protein in
response to IFNg (Figure 5C). Interestingly, addition of
exogenous PGE2 neither modified PD-L1 expression in
NAF nt nor rescued IFNg-induced PD-L1 expression in
NAF COX-2KD cells.
To assess how critical the loss of COX-2’s immune
suppressive actions was for reduced tumor growth and
burden, we examined growth of NAF COX-2KD ortho-
topic tumors in recipient mice treated with an anti-CD8
Figure 3 Deletion of mammary epithelial COX-2 modified tumor infiltrating cell phenotype. COX-2MECKO tumors are denoted as KO.
(A) Flow cytometry analysis of tumor associated lymphocytes and macrophages (n = 7 to 10). (B) Gene expression levels measured by Q-PCR in
CD45+ tumor infiltrating leukocytes (TILs) isolated from whole tumors by microbead separation (n = 6 to 7). (C) Gene expression levels measured
by Q-PCR in unpolarized, M1 polarized or M2 polarized bone marrow derived macrophages, treated without or with PGE2 (n = 8). Data are
mean ± sem. P values are compared to WT; *p < 0.05. COX, cyclooxygenase; KO, knock out; PGE2, prostaglandin E2; WT, wild type.
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Figure 4 COX-2 suppresses immune surveillance by altering T cell recruitment and activation. COX-2MECKO tumors are denoted as KO.
(A) Immunohistochemistry staining for CXCL9 (brown) of sections from paraffin embedded WT and COX-2MECKO tumors (two images from each
genotype shown are representative of n = 4). Nuclei are counterstained with hematoxylin. The bar on the KO panel corresponds to 40×
magnification. (B) Gene expression levels measured by Q-PCR in whole tumors (n = 8 to 18). Data are mean ± sem. P values are compared to
WT; *P < 0.05. COX, cyclooxygenase; KO, knock out; WT, wild type.
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antibody, to deplete CD8+ immune cells, or an isotype
control antibody. Complete depletion of CD8+ cells in
blood was confirmed by flow cytometry (Figure 6A). In
isotype control antibody treated mice NAF COX-2KD
grew poorly in only two of six injections. In contrast, six
of six NAF COX-2KD tumors grew in CD8+ depleted
mice, similar to NAF nt control cells (Figure 6B), and
were markedly larger at necroscopy (four weeks after
tumor injection; Figure 6C).
Discussion
Significant attention is now focused on understanding
how resident and infiltrating cells in the tumor microen-
vironment support disease progression and in developing
therapeutic strategies directed at microenvironmental
targets [7]. Central to the pro-tumor microenvironment
is suppression of immune cell function allowing tumor
cells to avoid destruction. In the current study, we
demonstrated enhanced immune cell recruitment and
reduced T cell co-inhibitory pathways in tumors that lack
mammary epithelial expression of the pro-inflammatory
enzyme COX-2, coincident with delayed ErbB2 onco-
gene-driven mammary tumor development.
Consistent with established paradigms of COX-2 in
cancer [6,35,36], deletion of MEC COX-2 delayed mam-
mary tumor onset, lowered tumor multiplicity, reduced
tumor cell proliferation and decreased tumor vasculariza-
tion. Reduced vascularization in COX-2MECKO tumors
was associated with lower expression of VEGFA and its
receptor VEGFR2, a dominant pro-angiogenic pathway in
tumors [37], consistent with the role of COX-2 in pro-
moting the angiogenic switch that allows tumors to pro-
gress [38]. It may be that reduced tumor cell proliferation
and suppressed angiogenesis associated with deletion of
MEC COX-2 was sufficient to suppress tumors. How-
ever, the elevation of CD4+ and CD8+ immune cell popu-
lations we observed in COX-2MECKO mice, prompted us
to consider how tumor cell COX-2 contributes to tumor
immune function.
COX-2-mediated promotion of pro-tumorigenic Th2
lymphocyte and M2 macrophage functional phenotypes,
as well as suppression of cytotoxic immune cell activity,
has been reported [6]. However, it remains unclear how
COX-2 contributes to the orchestration of immune cell
function as tumors develop. In part, the paucity of infor-
mation reflects the difficulties of working with global
COX-2 knock out mice, which have breeding problems,
severe renal pathology and a shortened life span [39],
none of which are encountered in our targeted COX-
2MECKO mice, as well as the extensive use of immune
deficient host mice for tumor transplant studies.
Compared to WT, three populations of immune cells -
CD3+CD4+, which are Th lymphocytes, CD3
+CD8+ cells,
which are CTLs and CD3-CD8+, which encompass NKs
and dendritic cells - were elevated in COX-2MECKO
tumors. Within the CD3+CD4+ population, an increase
in anti-tumorigenic Th1 cells may suppress tumors in
COX-2MECKO mice; however, greater activity of Th2
lymphocytes and/or Treg would be expected to promote
tumor growth [24]. The strong trend towards an
increased T-bet/GATA3 mRNA ratio, a measure of the
Th1 to Th2 balance [40], and the unchanged expression
of FoxP3, a marker for Treg [6,24], indicates the likely
prevalence of the pro-immune helper function of Th1
lymphocytes over pro-tumorigenic Th2 lymphocytes or
immune suppressive Tregs, in COX-2
MECKO tumors.
These data are consistent with the shift toward type 1
immunity we reported previously in carcinogen-induced
mammary tumors in COX-2MECKO mice, which were
also delayed compared to WT [17].
Within the CD8+ populations, the suppressed tumor
phenotype in COX-2MECKO mice may result from
increased cytolytic actions of CTLs and NKs [24], as well
as enhanced immunogenic actions of mature dentritic
Figure 5 COX-2 knock down reduced tumor cell PD-L1
expression and orthotopic tumor growth. ErbB2-transformed
mammary epithelial cells (NAF) were transduced with non-targeted
shRNA (NAF nt) or COX-2 targeted shRNA (NAF COX-2KD). (A) COX-
2 mRNA levels measured by Q-PCR, after 24 hours of treatment with
5 μg/ml LPS (n = 4). (B) Percent of tumor free mice after mammary
fat pad injection of NAF nt and NAF COX-2KD (n = 6). (C) Mean
fluorescence of PD-L1 in NAF, measured by flow cytometry, after
48 hours of treatment with 10 ng/ml IFNg, with or without 250 nM
PGE2 (n = 3 to 6). Data in column graphs are mean ± sem. P values
are compared to NAF nt control, unless otherwise indicated. *P <
0.05, **P < 0.005, ***P < 0.0005. COX, cyclooxygenase; KO, knock
out; shRNA, short hairpin RNA.
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cells [41]. We did not directly discriminate between the
relative contributions of these CD8+ subtypes; however, a
key role for CD8+ immune cells in COX-2-mediated con-
trol of tumor immune function is strongly supported by
the restoration of NAF COX-2KD tumor cell growth in
CD8+-depleted mice.
TAM are abundant in mammary tumors and their den-
sity is generally directly correlated with disease severity
and prognosis [42,43]. Similar to the Th1 and Th2 lym-
phocyte characterization, M1 and M2 macrophages are
considered anti- and pro- tumor, respectively [44]. We
reported previously that COX-2-derived PGE2 restrains
M1 macrophage polarization in vitro and in carcinogen-
induced mammary tumors [17]. In the current model,
however, CD86, a M1 macrophage marker, was not dif-
ferent in COX-2MECKO tumor associated F4/80+ cells
(macrophages) or in isolated CD45+ TILs, compared to
WT. It is likely that the relevance of COX-2-mediated
paracrine control of M1 macrophage function to tumor
progression varies between models. Retnla (Resistin-like
molecule alpha/FIZZ1), a cytokine derived from alterna-
tively activated M2 type macrophages [45], was signifi-
cantly lower in CD45+ TILs from COX-2MECKO tumors
suggesting reduced M2 polarization, a possible reflection
of reduced Th2-derived cytokines in the COX-2
MECKO
microenvironment and/or loss of paracrine COX-2-
derived PGE2 activity, which augments M2 polarization
of BMDM in vitro.
As a whole, our analysis of the tumor microenviron-
ment strongly supported a shift towards enhanced helper
and effector T lymphocyte recruitment and function in
COX-2MECKO tumors. It may be that there is simply an
increased immune cell recruitment to breast tumors lack-
ing epithelial COX-2. Indeed, we saw a dramatic increase
Figure 6 CD8+ cell depletion restores growth of injected NAF COX-2KD tumor cells as orthotopic tumors. (A) Flow cytometry of
peripheral blood from anti-CD8 or isotype control antibody treated mice four days after mammary fat pad injection (representative of n = 6).
(B) Tumor growth of NAF nt and NAF COX-2KD cells injected into mammary fat pads of mice that received either anti-CD8 or isotype control
antibody injection (antibody treatment denoted with ^ along X axis; n = 6). (C) NAF COX-2KD tumor volume measured on necropsy of animals
that were treated with either isotype control or anti-CD8 antibody. In B and C data are mean ± sem of n = 6. **P < 0.005, ***P < 0.0005. COX,
cyclooxygenase.
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in tumor cell expression of the T cell chemokine CXCL9
in COX-2MECKO tumors, consistent with a recent report
in patients with invasive breast cancer that tumor cells
are the major source of CXCL9 [12]. In the same study,
PGE2 suppressed IFNg-induced CXCL9 levels in MCF-7
and MDA-MB 231 breast cancer cells, and COX inhibi-
tors increased CXCL9 secretion. Despite the higher
CXCL9 levels in COX-2MECKO tumors, however, the
absolute number of CD3+ cells by flow cytometry was
not higher than in WT tumors suggesting a local influ-
ence of tumor cell COX-2 derived mediators in limiting
immune cell function rather than a simple recruitment
effect.
Intense interest in cancer immunotherapy has focused
recently on immune checkpoints, whose function to
dampen immune responses is important for self toler-
ance and control of physiological immune responses.
Two central and well-studied immune checkpoints are
the co-inhibitory receptors CTLA4 and PD-1; antago-
nists to both are currently in clinical trials for melanoma
and other cancers [32]. Engagement of CLTA4 or PD-1
on immune cells by their ligands CD80/CD86 or PD-L1,
respectively, can suppress or shut down immune surveil-
lance [46]. Conversely, blockade of co-inhibitory recep-
tor-ligand interaction can enhance anti-tumor immunity
[32]. In our study, levels of CTLA4 and PD-1, as well as
PD-L1, were decreased in COX-2MECKO tumors. The
PD-1-PD-L1 interaction is of particular interest in this
regard since PD-1 expression in tissues is induced by
inflammatory signals where it acts to suppress T cell
activity and limit collateral tissue damage [32]. We rea-
soned, therefore, that COX-2, an established inflamma-
tory gene, may act in tumors to upregulate expression
of PD-1/PD-L1, thereby suppressing immune function
and facilitating immune escape. In support of this
hypothesis, NAF COX-2KD, which grew very poorly as
orthotopic tumors, generated substantially less PD-L1 in
response to IFNg compared to NAF nt control cells.
The failure of exogenous PGE2 to restore PD-L1 expres-
sion levels in NAF COX-2KD may suggest distinct
actions of autocrine and paracrine PGE2, or indicate a
role for other COX-2-derived products, in tumor cell
COX-2 mediated control of PD-1 expression. The path-
ways through which COX-2-derived PGE2/other prosta-
noids control tumor cell expression of PD-L1 and other
immune modulators are currently under investigation.
Our study provides significant insight into the complex
autocrine and paracrine functions of mammary epithelial
COX-2 in ErbB2-induced breast cancer and suggests that
tumor cell COX-2 is an important component in estab-
lishing a permissive immune microenvironment. Recent
studies indicated that CD8+ tumor infiltration bolstered
chemotherapeutic responses in human breast cancer and
mouse models [8]. Our demonstration that deletion of
tumor cell COX-2 can enhance tumor-associated CD8+
cytotoxic immune cell infiltration and function may open
new avenues to develop targeted strategies for COX-2
inhibition in combination with cytotoxic drugs. Further,
there have been significant advances in cancer immu-
notherapy using antibodies to block CTLA4 or PD-1 co-
inhibitory function, thereby augmenting anti-tumor
immunity [32,47-49]. To our knowledge, our study is the
first to link COX-2 to T cell co-inhibitory receptor/ligand
function, a potentially new avenue to investigate COX-2
inhibitors as adjuvants to immunotherapy. Finally, we
demonstrated that interruption of COX-2 function selec-
tively in epithelial cells was sufficient to reduce ErbB2-
(this study) and carcinogen [17] induced mammary
tumorigenesis and growth. The clinical use of systemic
COX-2 inhibitors in cancer, although supported across
multiple studies [1], is limited by the associated gastroin-
testinal and cardiovascular hazards [50]. We speculate
that, as improved targeted drug delivery modalities con-
tinue to emerge, delivery of COX-2 selective inhibitors
directly to the tumor cells may allow for safe and effec-
tive use of these drugs in cancer without the deleterious
side effects associated with systemic COX inhibition.
Conclusions
The data strongly support that, in addition to its angio-
genic function, tumor cell COX-2-derived mediators
suppress anti-tumor immune cell function, possibly
through upregulation of inhibitory immune checkpoints,
contributing to tumor immune escape. COX-2 inhibi-
tion may be clinically useful to augment breast cancer
immunotherapy.
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